Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
6.85
-0.30 (-4.20%)
At close: Aug 14, 2025, 4:00 PM
6.87
+0.02 (0.29%)
After-hours: Aug 14, 2025, 5:49 PM EDT
Exicure Employees
Exicure had 7 employees as of December 31, 2024. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,126,143
Market Cap
43.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | 1 | 16.67% |
| Dec 31, 2023 | 6 | -7 | -53.85% |
| Dec 31, 2022 | 13 | -34 | -72.34% |
| Dec 31, 2021 | 47 | -16 | -25.40% |
| Dec 31, 2020 | 63 | 34 | 117.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
XCUR News
- 6 days ago - Exicure, Inc. Reports Second Quarter 2025 Financial Results - Business Wire
- 10 days ago - Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - Business Wire
- 13 days ago - Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 6 weeks ago - Exicure, Inc. Reports First Quarter 2025 Financial Results - Business Wire
- 2 months ago - Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
- 3 months ago - Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 4 months ago - Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - Business Wire
- 4 months ago - Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - Business Wire